Top-Rated StocksTop-RatedNASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free MDGL Stock Alerts $283.23 +12.86 (+4.76%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$272.01▼$292.8650-Day Range$171.37▼$283.2352-Week Range$119.76▼$322.67Volume963,934 shsAverage Volume578,717 shsMarket Capitalization$5.64 billionP/E RatioN/ADividend YieldN/APrice Target$369.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Madrigal Pharmaceuticals alerts: Email Address Madrigal Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside30.4% Upside$369.40 Price TargetShort InterestBearish21.40% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.70Based on 54 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($21.40) to ($9.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.70 out of 5 starsMedical Sector184th out of 947 stocksPharmaceutical Preparations Industry80th out of 435 stocks 4.5 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $369.40, Madrigal Pharmaceuticals has a forecasted upside of 30.4% from its current price of $283.23.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.40% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 2.06%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -0.92. Previous Next 3.2 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 54 news articles for Madrigal Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest55 people have searched for MDGL on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.MarketBeat Follows29 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 26% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.86% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($21.40) to ($9.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -14.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -14.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 13.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Read More MDGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDGL Stock News HeadlinesMarch 19, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingMarch 18, 2024 | globenewswire.comMadrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 18, 2024 | msn.comMadrigal Pharmaceuticals commences underwritten public offeringMarch 18, 2024 | globenewswire.comMadrigal Pharmaceuticals Announces Proposed Public OfferingMarch 17, 2024 | fool.comMadrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?March 17, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up to $243.57March 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 16, 2024 | msn.comMadrigal (NASDAQ:MDGL) Rezdiffra Receives FDA Approval as First-Ever NASH TreatmentMarch 16, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded by B. Riley to "Neutral"March 15, 2024 | msn.comFDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With ScarringMarch 15, 2024 | reuters.comMadrigal Pharma surges after drug wins first approval for fatty liver disease NASHMarch 15, 2024 | msn.comMadrigal Pharmaceuticals Soars After Getting FDA Approval for Liver-Scarring TreatmentMarch 15, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease TreatmentMarch 15, 2024 | finance.yahoo.comGeron, Madrigal Pharmaceuticals jump on good news from FDAMarch 15, 2024 | finance.yahoo.comMadrigal Stock Soars 11% After FDA Approved The First MASH TreatmentMarch 15, 2024 | seekingalpha.comMadrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 ChallengeMarch 15, 2024 | proactiveinvestors.comMadrigal Pharmaceuticals wins FDA approval for liver disease drug; shares soarMarch 15, 2024 | investorplace.comMDGL Stock Alert: The Historic Reason Madrigal Is Up 19% TodayMarch 15, 2024 | msn.comDoorDash upgraded, GM initiated: Wall Street's top analyst callsMarch 15, 2024 | finance.yahoo.comMDGL Mar 2024 330.000 putMarch 15, 2024 | reuters.comMadrigal Pharma surges on FDA nod to first drug for fatty liver disease NASHMarch 15, 2024 | finance.yahoo.comMDGL Oct 2024 120.000 putMarch 15, 2024 | markets.businessinsider.comMadrigal Pharma: Rezdiffra Gets First FDA Approval For NASHMarch 15, 2024 | markets.businessinsider.comBuy Rating on Madrigal Pharmaceuticals: Rezdiffra’s Market Potential Undervalued Post-FDA ApprovalMarch 14, 2024 | reuters.comUS FDA approves first drug for fatty liver disease NASHSee More Headlines Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/18/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees376Year Founded2011Price Target and Rating Average Stock Price Target$369.40 High Stock Price Target$425.00 Low Stock Price Target$270.00 Potential Upside/Downside+30.4%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($19.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-373,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-219.39% Return on Assets-98.75% Debt Debt-to-Equity Ratio0.28 Current Ratio5.38 Quick Ratio5.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.53 per share Price / Book13.80Miscellaneous Outstanding Shares19,900,000Free Float15,138,000Market Cap$5.64 billion OptionableOptionable Beta-0.48 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Rebecca A. Taub M.D. (Age 72)Founder, Chief Medical Officer, President of Research & Development and Director Comp: $939.83kMr. Alex G. Howarth (Age 54)Senior VP & CFO Comp: $757.26kMr. Brian J. Lynch J.D. (Age 62)Senior VP & General Counsel Comp: $763.75kMr. William J. Sibold (Age 58)CEO, President & Director Mr. Ronald FilippoChief Information OfficerMs. Tina E. VenturaChief Investor Relations OfficerDr. Kianoush Motesharei Ph.d. (Age 54)Senior Vice President of Business & Corporate Development Mr. Clint WallaceChief Human Resources OfficerMr. Edward ChiangSenior Vice President of Clinical & Technical OperationsMr. Thomas W. HareSenior Vice President of Clinical ManagementMore ExecutivesKey CompetitorsAlkermesNASDAQ:ALKSIonis PharmaceuticalsNASDAQ:IONSAmicus TherapeuticsNASDAQ:FOLDDicerna PharmaceuticalsNASDAQ:DRNARocket PharmaceuticalsNASDAQ:RCKTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,404 shares on 3/11/2024Ownership: 7.913%Wellington Management Group LLPBought 5,227 shares on 3/5/2024Ownership: 0.026%American International Group Inc.Bought 558 shares on 2/28/2024Ownership: 0.037%Perceptive Advisors LLCBought 26,514 shares on 2/26/2024Ownership: 0.766%Virtu Financial LLCBought 4,063 shares on 2/26/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions MDGL Stock Analysis - Frequently Asked Questions Should I buy or sell Madrigal Pharmaceuticals stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDGL shares. View MDGL analyst ratings or view top-rated stocks. What is Madrigal Pharmaceuticals' stock price target for 2024? 10 equities research analysts have issued twelve-month target prices for Madrigal Pharmaceuticals' shares. Their MDGL share price targets range from $270.00 to $425.00. On average, they expect the company's share price to reach $369.40 in the next year. This suggests a possible upside of 30.4% from the stock's current price. View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts. How have MDGL shares performed in 2024? Madrigal Pharmaceuticals' stock was trading at $231.38 at the beginning of the year. Since then, MDGL stock has increased by 22.4% and is now trading at $283.23. View the best growth stocks for 2024 here. When is Madrigal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MDGL earnings forecast. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.26) by $0.42. During the same period in the previous year, the company posted ($4.98) EPS. What ETFs hold Madrigal Pharmaceuticals' stock? ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Alger Mid Cap 40 ETF (FRTY), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Pharmaceuticals ETF (IHE).Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild). Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.57%), Vanguard Group Inc. (7.98%), Vanguard Group Inc. (7.91%), Paulson & CO. Inc. (5.60%), RTW Investments LP (4.13%) and Price T Rowe Associates Inc. MD (1.97%). Insiders that own company stock include Brian Joseph Lynch, Bros Advisors Lp Baker, Remy Sukhija, Richard S Levy and Robert E Waltermire. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MDGL) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.